Protecting Clients Coast to Coast

For 30 years, Faruqi & Faruqi has been dedicated to protecting the rights of shareholders, employees, and consumers through integrity, respect, and results. 

Who We Are

Over 30 Years Of Working Experience In Legal Solutions

Faruqi & Faruqi, LLP’s national practice focuses on complex civil litigation. The firm practices in the areas of Securities, Merger & Transactional, Shareholder Derivative, Antitrust, Consumer Class Action and Wage & Hour litigation.

Take Action

View our active case list and determine whether you want to participate in an action with us now
View All
Inform us of any fraud or unfair business practice using the link below
Report a Fraud
A class action suit can provide merger scrutiny to ensure you are protected
Merger Information
What we do

Client Services

Faruqi & Faruqi strives to provide exceptional client services. These services include:
Portfolio Monitoring
We review the investment portfolios of institutional clients and prepare detailed reports.
Learn More
Corporate Governance and Regulatory Compliance
We monitor changes in the law to protect shareholders from corporate non-compliance.
Learn More
Case Evaluation
We perform complex damage analyses to evaluate the merit of clients’ cases.
Learn More
Practice Areas

Our Legal Work

Faruqi & Faruqi, LLP focuses on complex civil litigation, including securities, antitrust, wage and hour and consumer class actions as well as shareholder derivative and merger and transactional litigation. The firm is headquartered in New York, and maintains offices in California, Georgia, and Pennsylvania.

Are You an Affected Shareholder?

Faruqi & Faruqi, LLP is actively investigating the following cases:
6 Oct 2025
Molina Healthcare, Inc.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Molina To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Molina between February 5, 2025 and July 23, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Molina Healthcare, Inc. (“Molina” or the “Company”) (NYSE: MOH) and reminds investors of the December 2, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose: (1) material, adverse facts concerning the Company’s “medical cost trend assumptions;” (2) that Molina was experiencing a “dislocation between premium rates and medical cost trend;” (3) that Molina’s near term growth was dependent on a lack of “utilization of behavioral health, pharmacy, and inpatient and outpatient services;” (4) as a result of the foregoing, Molina’s financial guidance for fiscal year 2025 was substantially likely to be cut; and (5) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. On July 7, 2025, before the market opened, Molina issued a press release announcing financial results for the second quarter of 2025 and slashing full year 2025 adjusted earnings per share guidance. The press release revealed the Company’s second quarter 2025 adjusted earnings of approximately $5.50 per share, which was “below its prior expectations” due to “medical cost pressures in all three lines of business.” The Company announced it “expects these medical cost pressures to continue into the second half of the year” and cut guidance for expected adjusted earnings per share 10.2% at the midpoint, from “at least $24.50 per share” to a “range of $21.50 to $22.50 per share.” The press release revealed Molina was experiencing a “short-term earnings pressure” from a “dislocation between premium rates and medical cost trend which has recently accelerated.” On this news, Molina’s stock price fell $6.97, or 2.9%, to close at $232.61 per share on July 7, 2025, on unusually heavy trading volume. Then, on July 23, 2025, after the market closed, Molina issued a press release reporting its financial results for the second quarter ended June 30, 2025 and further slashing the Company’s full-year 2025 earnings guidance. The press release revealed, in part, that the Company’s “GAAP net income was $4.75 per diluted share for the second quarter of 2025, a decrease of 8% year over year;” and it “now expects its full year 2025 adjusted earnings to be no less than $19.00 per diluted share.” This represented another 13.6% cut to guidance of earnings per share at the midpoint, from the cut to guidance announced less than two weeks earlier. The Company also cut its guidance for its full year 2025 GAAP net income 27% to $912 million. The Company attributed its results a full year outlook to a “challenging medical cost trend environment,” including mere “utilization of behavioral health, pharmacy, and inpatient and outpatient services.” The Company alleged its guidance cut also reflected “new information gained in the quarterly closing process.” On this news, Molina’s stock price fell $32.03, or 16.84%, to close at $158.22 per share on July 24, 2025, on unusually heavy trading volume. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Molina’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Molina Healthcare, Inc. class action, go to www.faruqilaw.com/MOH or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
James M. Wilson, Jr.
Robert W. Killorin
Lead Plaintiff Deadline
56 Days
Take Action
29 Sep 2025
MoonLake Immunotherapeutics
If you suffered significant losses in MoonLake stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX). Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. MoonLake Immunotherapeutics saw its shares plummet over 80% on Monday after disappointing results from two late-stage trials of its experimental drug, sonelokimab, for hidradenitis suppurativa. While one study showed a statistically significant improvement over placebo, the margin of benefit fell short of investor expectations. The second trial failed to meet its primary endpoint entirely, with the company citing an unexpectedly high placebo response. The underwhelming data has cast doubt on the drug’s regulatory path and commercial potential, prompting skepticism from analysts and a sharp market sell-off. To learn more about the MoonLake investigation, go to www.faruqilaw.com/MLTX or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising.  The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.comv).  Prior results do not guarantee or predict a similar outcome with respect to any future matter.  We welcome the opportunity to discuss your particular case.  All communications will be treated in a confidential manner.
James M. Wilson, Jr.
Robert W. Killorin
Take Action
22 Sep 2025
Quanex Building Products Corporation
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Quanex To Contact Him Directly To Discuss Their Options If you suffered losses in Quanex between December 12, 2024 and September 5, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Quanex Building Products Corporation (“Quanex” or the “Company”) (NYSE: NX) and reminds investors of the November 18, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the Company’s procedures and policies regarding tooling and equipment maintenance in its Tyman Mexico facility were significantly “underinvested”; (2) as a result, the Company’s tooling and equipment conditions had significantly degraded to near “catastrophic” levels; (3) that, as a result of the foregoing, the Company was likely to incur significant costs, “pushing out the timing” of expected benefits from the Tyman integration; (4) that Quanex had previously identified the foregoing issues; and (5) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. On September 4, 2025, after the market closed, Quanex announced financial results for the third quarter of the 2025 fiscal year. Among other things, the Company disclosed “operational issues related to the legacy Tyman window and door hardware business in Mexico that are ongoing” which “impacted results more than expected during the third quarter of 2025.” Specifically, the Company reported a diluted EPS of ($6.04), compared to $0.77 in the prior year period and an adjusted EBIDTA of $70.30. The Company further disclosed that it was “adjusting for lower expected volumes and pushing out the timing of when [it] expect[s] to realize procurement savings” from the integration of the Tyman business. Then, on September 5, 2025, the Company held an earnings call pursuant to the Company’s third quarter 2025 financial results. During the earnings call, Chief Executive Officer, George Wilson (“Wilson”) explained “operational challenges” in the Tyman facility in Mexico “negatively impacted EBITDA in the Hardware Solutions segment by almost $5 million in the third quarter alone.” Wilson further explained that the issue was previously “identified midyear” as it got “deeper into the integration” with Tyman, and described how the systems used to “anticipate and plan for tooling repairs” were significantly deficient, indicating it was near “nonexistent.” Wilson stated because Quanex was “underinvested” in “the tooling condition and the equipment condition” it “had to make some changes and fix some things before it was catastrophic.” On this news, Quanex’s stock price fell $2.73, or 13.1%, to close at $18.18 per share on September 5, 2025, on unusually heavy trading volume. The stock price continued to decline on the subsequent trading day, falling $1.98 or 10.9%, to close at $16.20 per share on September 8, 2025, on unusually heavy trading volume. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Quanex’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Quanex Building Products class action, go to www.faruqilaw.com/NX or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
James M. Wilson, Jr.
Robert W. Killorin
Lead Plaintiff Deadline
42 Days
Take Action
22 Sep 2025
KBR, Inc.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In KBR To Contact Him Directly To Discuss Their Options If you suffered losses in KBR between May 6, 2025 and June 19, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against KBR, Inc. (“KBR” or the “Company”) (NYSE: KBR) and reminds investors of the November 18, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Despite the knowledge that the U.S. Department of Defense’s Transportation Command (TRANSCOM) had, for months, had material concerns with HomeSafe’s ability to fulfill the Global Household Goods Contract, defendants claimed that the partnership was without issue, and would ramp up in future quarters; and (2) as a result, defendants statements about KBR’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. On June 19, 2025, after the market closed, HomeSafe issued a press release entitled “HomeSafe Alliance announces TRANSCOM’s Notice to Terminate Global Household Goods Contract.” The next day, before market hours, KBR issued a press release entitled “KBR Announcement on HomeSafe Alliance Global Household Goods Contract.” On this news, the price of KBR stock fell $3.85 per share, or 7.29%, to close at $48.93 on June 20, 2025. On June 23, 2025, the next trading day, KBR stock fell a further $1.30, or 2.65%, to close at $47.63 on June 23, 2025. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding KBR’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the KBR class action, go to www.faruqilaw.com/KBR or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
James M. Wilson, Jr.
Robert W. Killorin
Lead Plaintiff Deadline
42 Days
Take Action
Testimonials

Court Praises

Updates from Us

Latest News

See All
12 Sep 2025
Faruqi & Faruqi Beats Motion to Dismiss in Luminar Technologies Securities Litigation and Advances the Case to Discovery
Read More
4 Sep 2025
Faruqi & Faruqi Beats Motion to Dismiss in Sun-Maid Litigation
Read More
7 Apr 2025
Faruqi & Faruqi, LLP has been ranked in Chambers and Partner’s New York Chambers Spotlight 2025 Guide and recognized as a leader in the employment litigation industry
Read More

From the Blog

See All
1 Oct 2025
Broad Definition of “Hiring Party” Under FIFA Strengthens Workers’ Wage Rights
Read More
23 Sep 2025
The Ninth Circuit Finds That Fractional Interests In “Death Bets” Are Securities, Joining Circuit Split
Read More
23 Sep 2025
Assignee Take Care – Burford Capital’s Gets a Workout
Read More

Our Offices

Our offices are nationwide. If you have any questions about a case or our firm, please contact us.
Send Us a Message
New York
685 Third Avenue 26th Floor
New York New York 10017
(877) 247-4292 / (212) 983-9330
(212) 983-9331
Los Angeles
1901 Avenue of the Stars Suite 1060
Los Angeles California 90067
(424) 256-2884
(424) 256-2885
Atlanta
3565 Piedmont Road NE Building Four, Suite 380
Atlanta Georgia 30305
(404) 847-0617
(404) 506-9534
Philadelphia
1617 JFK Boulevard, Suite 1550 Philadelphia
Pennsylvania 19103
(215) 277-5770
(215) 277-5771